The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).

Giant cell arteritis, or GCA, is a condition where arteries in the head and neck become inflamed. It is called ‘giant cell’ because abnormally large cells accumulate in the artery walls.